Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
May 21, 2014
NEWARK, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), announced that the company's proprietary, botulinum toxin (BoNTA) investigational products will be the lead topics discussed in the Emerging Technologies panel at the 11th International Symposium of Facial Plastic Surgery in New York. Presentation: Th...
May 21, 2014
NEWARK, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Jefferies 2014 Global Healthcare Conference in New York. Revance management is scheduled to present on Monday, June 2, 2014 at 8:00 am ET. Interested parties can access the live audio ...
May 13, 2014
NEWARK, Calif., May 13, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three months ended March 31, 2014. Revance's operating loss for the three months ended March 31, 2014 was $11.5 million. Cash and cash equivalents as of March 31, 2014 were $87.9 million.Recent Accomplishments and Prog...
May 12, 2014
NEWARK, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Mark A. Prygocki has been appointed to its Board of Directors and as the Chair of its Audit Committee, effectiv...
Apr 29, 2014
NEWARK, Calif., April 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release first quarter 2014 financial results on Tuesday, May 13, 2014 after the close of ma...
Apr 21, 2014
NEWARK, Calif., April 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. RT002 is Revance's proprietary, injectable botulinum toxin investigational product that incorp...
Mar 31, 2014
NEWARK, Calif., March 31, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014. The Russell 2000® Index measures ...
Mar 26, 2014
NEWARK, Calif., March 26, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three and twelve months ended December 31, 2013.Recent Accomplishments and Progress Toward Milestones Closing of the Company's initial public offering (IPO) in February 2014, resulting in net proceeds of $102.7 ...
Mar 12, 2014
NEWARK, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release fourth quarter and full year 2013 financial results on Wednesday, March 26, 2014 af...
Mar 5, 2014
NEWARK, Calif., March 5, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Angus C. Russell has been appointed as Chairman to its Board of Directors, effective immediately. Mr. Rus...
Page: FirstPrevious ...
10
NextLast
= add release to Briefcase
Shareholder Tools